KR20140107536A - 아포지질단백질 제형을 위한 용량 용법 - Google Patents

아포지질단백질 제형을 위한 용량 용법 Download PDF

Info

Publication number
KR20140107536A
KR20140107536A KR1020147020291A KR20147020291A KR20140107536A KR 20140107536 A KR20140107536 A KR 20140107536A KR 1020147020291 A KR1020147020291 A KR 1020147020291A KR 20147020291 A KR20147020291 A KR 20147020291A KR 20140107536 A KR20140107536 A KR 20140107536A
Authority
KR
South Korea
Prior art keywords
apolipoprotein
formulation
dose
fixed
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147020291A
Other languages
English (en)
Korean (ko)
Inventor
크레이그 레이너
Original Assignee
시에스엘 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011905368A external-priority patent/AU2011905368A0/en
Application filed by 시에스엘 리미티드 filed Critical 시에스엘 리미티드
Publication of KR20140107536A publication Critical patent/KR20140107536A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020147020291A 2011-12-21 2012-11-02 아포지질단백질 제형을 위한 용량 용법 Ceased KR20140107536A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011905368 2011-12-21
AU2011905368A AU2011905368A0 (en) 2011-12-21 Dosing regime for apolipoprotein formulations
PCT/AU2012/001345 WO2013090978A1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019295A Division KR20190084334A (ko) 2011-12-21 2012-11-02 아포지질단백질 제형을 위한 용량 용법

Publications (1)

Publication Number Publication Date
KR20140107536A true KR20140107536A (ko) 2014-09-04

Family

ID=48667485

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147020291A Ceased KR20140107536A (ko) 2011-12-21 2012-11-02 아포지질단백질 제형을 위한 용량 용법
KR1020197019295A Ceased KR20190084334A (ko) 2011-12-21 2012-11-02 아포지질단백질 제형을 위한 용량 용법
KR1020207009276A Active KR102766038B1 (ko) 2011-12-21 2012-11-02 아포지질단백질 제형을 위한 용량 용법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197019295A Ceased KR20190084334A (ko) 2011-12-21 2012-11-02 아포지질단백질 제형을 위한 용량 용법
KR1020207009276A Active KR102766038B1 (ko) 2011-12-21 2012-11-02 아포지질단백질 제형을 위한 용량 용법

Country Status (16)

Country Link
US (3) US20140378376A1 (enExample)
EP (1) EP2793913B1 (enExample)
JP (2) JP6144276B2 (enExample)
KR (3) KR20140107536A (enExample)
CN (2) CN104010646A (enExample)
AU (1) AU2012310259C1 (enExample)
BR (1) BR112014014403A8 (enExample)
CA (1) CA2857968A1 (enExample)
DK (1) DK2793913T3 (enExample)
ES (1) ES2955110T3 (enExample)
IL (1) IL233236A0 (enExample)
MX (1) MX377093B (enExample)
PL (1) PL2793913T3 (enExample)
RU (1) RU2014129505A (enExample)
SG (1) SG11201402556RA (enExample)
WO (1) WO2013090978A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9645037B2 (en) 2011-09-28 2017-05-09 Hunter Engineering Company Method and apparatus for wheel assembly lateral force measurement
CA2857968A1 (en) * 2011-12-21 2013-06-27 Csl Limited Dosage regime for apolipoprotein formulations
WO2018085890A1 (en) 2016-11-10 2018-05-17 Csl Limited Reconstituted high density lipoprotein treatment of myocardial infarction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152632A (ja) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
CA2460787A1 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
WO2004010939A2 (en) * 2002-07-30 2004-02-05 Esperion Therapeutics, Inc. Methods of using non-human animal apoliprotein a-i protein
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
CN1870894B (zh) * 2003-10-20 2011-08-10 埃斯普里昂治疗公司 用于治疗和预防急性冠状动脉综合征的药物制剂、方法和给药方案
WO2007023476A2 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US20090297577A1 (en) * 2008-06-02 2009-12-03 Medtronic Vascular, Inc. Local Delivery of Apolipoproteins and Their Derivatives
CA2857968A1 (en) * 2011-12-21 2013-06-27 Csl Limited Dosage regime for apolipoprotein formulations

Also Published As

Publication number Publication date
KR20200037879A (ko) 2020-04-09
BR112014014403A8 (pt) 2021-03-09
AU2012310259A1 (en) 2013-07-11
JP2015500840A (ja) 2015-01-08
KR102766038B1 (ko) 2025-02-12
MX2014006589A (es) 2014-10-17
AU2012310259C1 (en) 2016-07-14
RU2014129505A (ru) 2016-02-10
HK1199813A1 (en) 2015-07-24
JP2017128586A (ja) 2017-07-27
EP2793913A1 (en) 2014-10-29
PL2793913T3 (pl) 2023-11-06
RU2017129700A (ru) 2019-02-04
US20160175392A1 (en) 2016-06-23
US20140378376A1 (en) 2014-12-25
BR112014014403A2 (pt) 2017-06-13
US20240216467A1 (en) 2024-07-04
DK2793913T3 (da) 2023-08-21
RU2017129700A3 (enExample) 2021-02-26
EP2793913B1 (en) 2023-06-21
CN104010646A (zh) 2014-08-27
EP2793913A4 (en) 2015-06-10
NZ624558A (en) 2015-08-28
WO2013090978A1 (en) 2013-06-27
JP6144276B2 (ja) 2017-06-07
SG11201402556RA (en) 2014-10-30
KR20190084334A (ko) 2019-07-16
MX377093B (es) 2025-03-07
CN113398245A (zh) 2021-09-17
AU2012310259B2 (en) 2015-07-30
CA2857968A1 (en) 2013-06-27
IL233236A0 (en) 2014-08-31
ES2955110T3 (es) 2023-11-28

Similar Documents

Publication Publication Date Title
US11957731B2 (en) Reconstituted HDL formulation
US20240216467A1 (en) Dosage regime for apolipoprotein formulations
RU2776110C2 (ru) Схема дозирования для составов аполипопротеина
HK1199813B (en) Dosage regime for apolipoprotein formulations
DK2916857T3 (en) RECONSTITUTED HDL FORMULATION
NZ624558B2 (en) Dosage regime for apolipoprotein formulations
HK40010383A (en) Reconstituted hdl formulation
HK1212599B (en) Reconstituted hdl formulation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171026

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190104

Patent event code: PE09021S01D

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190703

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190730

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190104

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I